Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00439465
Status:
COMPLETED
Last Update Posted:
2019-03-26
First Post:
2007-02-21
Brief Title:
Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma
Sponsor:
Dartmouth-Hitchcock Medical Center
Organization:
Dartmouth-Hitchcock Medical Center
Study Overview
Official Title:
Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether the administration of highly effective killer cells cytotoxic T cells along with Interleukin-2 IL-2 and Recombinant Human Granulocyte Colony Stimulating Factor GM-CSF immediately following Autologous Peripheral Blood Stem Cell Transplantation APBSCT will enhance anti-tumor immune reconstitution and improve outcome of Multiple Myeloma patients
The overall hypothesis of this proposal is that immediately following APBSCT the immune reconstitution is optimal to administer killer cells combined with the administration of IL-2 and GM-CSF
The overall hypothesis of this proposal is that immediately following APBSCT the immune reconstitution is optimal to administer killer cells combined with the administration of IL-2 and GM-CSF
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None